Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 3/20 | 0.54 |
| ▸ | GSK3B | P49841 | 15/20 | 0.52 |
| ▸ | DYRK1A | Q13627 | 15/20 | 0.52 |
| ▸ | CLK2 | P49760 | 1/20 | 0.47 |
| ▸ | CLK3 | P49761 | 1/20 | 0.47 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.46 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3665794 | 0.79 | GSK3B (0.58) | AXLGSK3BDYRK1ACLK2CLK3 | |
| SCHEMBL2661306 | 0.79 | LRRK2 (0.45) | AXLGSK3BDYRK1ACLK2 | |
| SCHEMBL2660282 | 0.79 | AXL (0.65) | AXLGSK3BDYRK1APRMT5WDR77 | |
| SCHEMBL26395150 | 0.78 | GSK3B (0.62) | AXLGSK3BDYRK1ACLK2CLK3 | |
| Hydrochloric Acid SCHEMBL26130176 | 0.78 | GSK3B (0.61) | AXLGSK3BDYRK1ACLK2CLK3 | |
| Hydrochloric Acid SCHEMBL31243398 | 0.78 | GSK3B (0.61) | AXLGSK3BDYRK1ACLK2CLK3 | |
| SCHEMBL2661291 | 0.76 | CDC7 (0.41) | GSK3BDYRK1ACLK2 | |
| SCHEMBL19998630 | 0.76 | AXL (0.65) | AXLGSK3BDYRK1ACLK2CLK3 | |
| SCHEMBL16014211 | 0.75 | AXL (0.64) | AXLGSK3BDYRK1ACLK2CLK3 | |
| SCHEMBL2661883 | 0.75 | GSK3B (0.54) | GSK3BDYRK1ACLK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110301155-A1 | INDAZOLE COMPOUNDS FOR ACTIVATING GLUCOKINASE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-12-08 | — | — | US | disclosed |
| US-20110301155-A1 | INDAZOLE COMPOUNDS FOR ACTIVATING GLUCOKINASE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-12-08 | — | — | US | disclosed |
| EP-2157859-A1 | INDAZOLE COMPOUNDS FOR ACTIVATING GLUCOKINASE | Takeda Pharmaceutical Company Limited (JP) | 2010-03-03 | — | — | EP | disclosed |
| WO-2008156757-A1 | INDAZOLE COMPOUNDS FOR ACTIVATING GLUCOKINASE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110301155-A1 | INDAZOLE COMPOUNDS FOR ACTIVATING GLUCOKINASE | GCKR, GCK, KHK | AXL 740/4885GSK3B 2134/4885DYRK1A 630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.